Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer
January 08, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 02, 2024
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
December 19, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
December 15, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares First-Quarter 2024 Dividend
December 14, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Completes Acquisition of Seagen
December 14, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Provides Full-Year 2024 Guidance
December 13, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
December 12, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
December 11, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
December 09, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
December 08, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
December 01, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 21, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
November 02, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 02, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Reports Third-Quarter 2023 Results
October 31, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
October 26, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
October 20, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
October 13, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
October 13, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
October 12, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases
October 05, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares Fourth-Quarter 2023 Dividend
October 04, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV
September 22, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 19, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
September 19, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
September 18, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 12, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
September 11, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
September 05, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.